UNH Stock Remains Undervalued Despite Strong Gain

UnitedHealth Group's stock has seen a significant gain of 15.4% so far this year, but despite this growth, it still appears to be undervalued according to several key metrics.

The company's current P/E ratio is around 24.7, which is lower than both the broader healthcare sector and its peer group on roughly 28.5x. This suggests that investors are not fully valuing the company's earnings potential yet.

Simply Wall St's model suggests a fair P/E multiple of 40.1x for UnitedHealth Group, reflecting factors such as profitability profile, scale, industry positioning, and risk. However, the current valuation is below this level, indicating a sizeable gap between price and what investors could reasonably expect to pay.

The sale of an interest in certain Florida WellMed clinics to TPG may support capital efficiency and margin repair, but execution risks around the wider Optum turnaround and cost pressures can weigh on investor sentiment.